In March 2025, the company declared new plans for the direct-to-buyer providing of its Wegovy weight loss drug. The company set up a completely new pharmacy, known as NovoCare, which would demand prospects $499 each month for access to the drug, below 50 percent the price of the drug via other pharmaceutical distribution networks.[fifty three]Other